S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
What Is WallStreetBets and What Stocks Are They Targeting?
Sell every Stock except ONE (Ad)
Closing prices for crude oil, gold and other commodities
2 Important Retail Stock Battles to Watch
Pipeline break spills 45,000 gallons of diesel in Wyoming
Biden's Plan to Confiscate Your Cash? (Ad)
Sinema took Wall Street money while killing tax on investors
MarketBeat: Week in Review 8/8 - 8/12
Expanded IRS free-file system one step closer in Dems' bill
Biden's Plan to Confiscate Your Cash? (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
What Is WallStreetBets and What Stocks Are They Targeting?
Sell every Stock except ONE (Ad)
Closing prices for crude oil, gold and other commodities
2 Important Retail Stock Battles to Watch
Pipeline break spills 45,000 gallons of diesel in Wyoming
Biden's Plan to Confiscate Your Cash? (Ad)
Sinema took Wall Street money while killing tax on investors
MarketBeat: Week in Review 8/8 - 8/12
Expanded IRS free-file system one step closer in Dems' bill
Biden's Plan to Confiscate Your Cash? (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
What Is WallStreetBets and What Stocks Are They Targeting?
Sell every Stock except ONE (Ad)
Closing prices for crude oil, gold and other commodities
2 Important Retail Stock Battles to Watch
Pipeline break spills 45,000 gallons of diesel in Wyoming
Biden's Plan to Confiscate Your Cash? (Ad)
Sinema took Wall Street money while killing tax on investors
MarketBeat: Week in Review 8/8 - 8/12
Expanded IRS free-file system one step closer in Dems' bill
Biden's Plan to Confiscate Your Cash? (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
What Is WallStreetBets and What Stocks Are They Targeting?
Sell every Stock except ONE (Ad)
Closing prices for crude oil, gold and other commodities
2 Important Retail Stock Battles to Watch
Pipeline break spills 45,000 gallons of diesel in Wyoming
Biden's Plan to Confiscate Your Cash? (Ad)
Sinema took Wall Street money while killing tax on investors
MarketBeat: Week in Review 8/8 - 8/12
Expanded IRS free-file system one step closer in Dems' bill
Biden's Plan to Confiscate Your Cash? (Ad)
NYSE:EBS

Emergent BioSolutions - EBS Stock Forecast, Price & News

$30.50
+0.61 (+2.04%)
(As of 08/12/2022 12:00 AM ET)
Add
Compare
Today's Range
$29.60
$30.87
50-Day Range
$27.42
$35.80
52-Week Range
$26.85
$65.09
Volume
1.13 million shs
Average Volume
673,223 shs
Market Capitalization
$1.52 billion
P/E Ratio
18.05
Dividend Yield
N/A
Price Target
$49.17

Emergent BioSolutions MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
61.2% Upside
$49.17 Price Target
Short Interest
Bearish
8.60% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.96
Upright™ Environmental Score
News Sentiment
-0.07mentions of Emergent BioSolutions in the last 14 days
Based on 5 Articles This Week
Insider Trading
Selling Shares
$107,891 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.70) to $2.00 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.41 out of 5 stars

Medical Sector

145th out of 1,117 stocks

Pharmaceutical Preparations Industry

60th out of 550 stocks

EBS stock logo

About Emergent BioSolutions (NYSE:EBS) Stock

Emergent BioSolutions Inc., a life sciences company, focuses on the provision of preparedness and response solutions that address accidental, deliberate, and naturally occurring public health threats (PHTs) in the United States. The company's products address PHTs, which include chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travel health; and emerging health crises and acute/emergency care. It offers BioThrax, an anthrax vaccine; ACAM2000, a smallpox vaccine; Botulism Antitoxin Heptavalent to treat botulinum disease; vaccinia immune globulin intravenous that addresses complications from smallpox vaccine; raxibacumab for the treatment and prophylaxis of inhalational anthrax; Anthrasil to for inhalational anthrax; reactive skin decontamination lotion kits; and Trobigard, a combination drug-device auto injector product candidate; and Trobigard, a combination drug-device auto injector product candidate. The company also provides NARCAN, a nasal spray for the emergency treatment of known or suspected opioid overdose; Vivotif, an oral vaccine for typhoid fever; and Vaxchora, a single-dose oral vaccine to treat cholera. In addition, it is developing AP003, a Naloxone multidose nasal spray; AP007, a sustained release Nalmefene injection for treatment of opioid use disorder; AV7909, an anthrax vaccine; CGRD-001, a pralidoxime chloride/atropine auto-injector; CHIKV VLP, a chikungunya virus VLP vaccine; COVID-HIG for the treatment of SARS-CoV2; EGRD-001, a diazepam auto-injector; SIAN, an antidote for the initial treatment of acute poisoning of cyanide; and UniFlu, a universal influenza vaccine. Further, the company provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.

Analyst Ratings Changes

Several equities analysts have recently weighed in on EBS shares. Cantor Fitzgerald lowered Emergent BioSolutions from an "overweight" rating to a "neutral" rating in a research note on Friday, April 29th. StockNews.com lowered Emergent BioSolutions from a "buy" rating to a "hold" rating in a research note on Saturday, May 7th. Cowen reduced their price objective on Emergent BioSolutions from $40.00 to $30.00 in a research note on Friday, April 29th. Chardan Capital reduced their price target on Emergent BioSolutions from $75.00 to $65.00 in a research report on Friday, April 29th. Finally, Cowen reduced their price target on Emergent BioSolutions from $40.00 to $30.00 in a research report on Friday, April 29th. Three research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus target price of $49.17.

Emergent BioSolutions Stock Up 2.0 %

Shares of EBS traded up $0.61 during trading on Friday, reaching $30.50. The company's stock had a trading volume of 1,130,178 shares, compared to its average volume of 670,304. The company has a fifty day moving average of $31.39 and a two-hundred day moving average of $36.67. Emergent BioSolutions has a twelve month low of $26.85 and a twelve month high of $65.09. The company has a market cap of $1.52 billion, a price-to-earnings ratio of 17.69 and a beta of 0.98. The company has a quick ratio of 2.38, a current ratio of 3.92 and a debt-to-equity ratio of 0.52.

Emergent BioSolutions (NYSE:EBS - Get Rating) last announced its earnings results on Monday, August 1st. The biopharmaceutical company reported ($0.86) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.38 by ($1.24). Emergent BioSolutions had a net margin of 6.02% and a return on equity of 12.22%. The business had revenue of $242.70 million during the quarter, compared to analyst estimates of $268.77 million. During the same period in the previous year, the company earned $0.33 earnings per share. The business's revenue for the quarter was down 38.9% on a year-over-year basis. On average, sell-side analysts predict that Emergent BioSolutions will post -0.7 EPS for the current fiscal year.

Insider Buying and Selling at Emergent BioSolutions

In other Emergent BioSolutions news, Director Kathryn C. Zoon sold 1,173 shares of the company's stock in a transaction that occurred on Thursday, June 9th. The stock was sold at an average price of $31.52, for a total value of $36,972.96. Following the transaction, the director now directly owns 19,654 shares of the company's stock, valued at approximately $619,494.08. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. In other news, Director Kathryn C. Zoon sold 1,173 shares of the business's stock in a transaction that occurred on Thursday, June 9th. The stock was sold at an average price of $31.52, for a total value of $36,972.96. Following the completion of the sale, the director now directly owns 19,654 shares in the company, valued at approximately $619,494.08. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Kathryn C. Zoon sold 1,996 shares of the business's stock in a transaction that occurred on Tuesday, May 24th. The shares were sold at an average price of $35.53, for a total value of $70,917.88. Following the completion of the sale, the director now owns 12,381 shares of the company's stock, valued at $439,896.93. The disclosure for this sale can be found here. 11.10% of the stock is currently owned by corporate insiders.

Receive EBS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Emergent BioSolutions and its competitors with MarketBeat's FREE daily newsletter.

EBS Stock News Headlines

See More Headlines
Receive EBS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Emergent BioSolutions and its competitors with MarketBeat's FREE daily newsletter.

EBS Company Calendar

Last Earnings
8/01/2022
Today
8/13/2022
Next Earnings (Estimated)
11/03/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
CUSIP
29089Q10
Employees
2,416
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$49.17
High Stock Price Forecast
$77.00
Low Stock Price Forecast
$30.00
Forecasted Upside/Downside
+61.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
4 Analysts

Profitability

Net Income
$230.90 million
Pretax Margin
8.45%

Debt

Sales & Book Value

Annual Sales
$1.79 billion
Cash Flow
$8.59 per share
Book Value
$30.35 per share

Miscellaneous

Free Float
44,327,000
Market Cap
$1.52 billion
Optionable
Optionable
Beta
0.98

Key Executives

  • Mr. Robert G. Kramer Sr. (Age 65)
    CEO, Pres & Exec. Director
    Comp: $1.93M
  • Mr. Richard S. Lindahl (Age 58)
    Exec. VP, CFO & Treasurer
    Comp: $858.61k
  • Mr. Adam R. Havey (Age 51)
    Exec. VP & COO
    Comp: $843.1k
  • Mr. Atul Saran (Age 49)
    Exec. VP & Chief Strategy and Devel. Officer
    Comp: $820.66k
  • Mr. Robert G. Burrows
    VP of Investor Relations
  • Ms. Jennifer L. Fox
    Exec. VP of External Affairs, Gen. Counsel & Corp. Sec.
  • Ms. Coleen Glessner
    Exec. VP of Global Quality and Ethics & Compliance
  • Ms. Lynn Kieffer
    VP of Corp. Communications
  • Ms. Katherine Strei (Age 60)
    Exec. VP of HR & Chief HR Officer













EBS Stock - Frequently Asked Questions

Should I buy or sell Emergent BioSolutions stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Emergent BioSolutions in the last twelve months. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" EBS shares.
View EBS analyst ratings
or view top-rated stocks.

What is Emergent BioSolutions' stock price forecast for 2022?

4 Wall Street analysts have issued 1-year target prices for Emergent BioSolutions' stock. Their EBS share price forecasts range from $30.00 to $77.00. On average, they predict the company's stock price to reach $49.17 in the next year. This suggests a possible upside of 61.2% from the stock's current price.
View analysts price targets for EBS
or view top-rated stocks among Wall Street analysts.

How have EBS shares performed in 2022?

Emergent BioSolutions' stock was trading at $43.47 on January 1st, 2022. Since then, EBS stock has decreased by 29.8% and is now trading at $30.50.
View the best growth stocks for 2022 here
.

When is Emergent BioSolutions' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 3rd 2022.
View our EBS earnings forecast
.

How were Emergent BioSolutions' earnings last quarter?

Emergent BioSolutions Inc. (NYSE:EBS) posted its earnings results on Monday, August, 1st. The biopharmaceutical company reported ($0.86) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.38 by $1.24. The biopharmaceutical company had revenue of $242.70 million for the quarter, compared to analysts' expectations of $268.77 million. Emergent BioSolutions had a trailing twelve-month return on equity of 12.22% and a net margin of 6.02%. The business's revenue was down 38.9% compared to the same quarter last year. During the same period in the previous year, the company posted $0.33 earnings per share.

What guidance has Emergent BioSolutions issued on next quarter's earnings?

Emergent BioSolutions updated its third quarter 2022 earnings guidance on Tuesday, August, 9th. The company provided EPS guidance of for the period. The company issued revenue guidance of $230.00 million-$270.00 million, compared to the consensus revenue estimate of $301.17 million.

What is Bob Kramer's approval rating as Emergent BioSolutions' CEO?

38 employees have rated Emergent BioSolutions Chief Executive Officer Bob Kramer on Glassdoor.com. Bob Kramer has an approval rating of 74% among the company's employees.

What other stocks do shareholders of Emergent BioSolutions own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Emergent BioSolutions investors own include NVIDIA (NVDA), Salesforce (CRM), Novavax (NVAX), Advanced Micro Devices (AMD), Block (SQ), Netflix (NFLX), Gilead Sciences (GILD), PayPal (PYPL), Johnson & Johnson (JNJ) and AbbVie (ABBV).

What is Emergent BioSolutions' stock symbol?

Emergent BioSolutions trades on the New York Stock Exchange (NYSE) under the ticker symbol "EBS."

Who are Emergent BioSolutions' major shareholders?

Emergent BioSolutions' stock is owned by many different retail and institutional investors. Top institutional investors include Northern Trust Corp (1.20%), Global Alpha Capital Management Ltd. (0.83%), Deutsche Bank AG (0.81%), Principal Financial Group Inc. (0.55%), Rice Hall James & Associates LLC (0.52%) and Russell Investments Group Ltd. (0.41%). Insiders that own company stock include Adam Havey, Fuad El-Hibri, George A Joulwan, Kathryn C Zoon, Louis W Sullivan, Richard S Lindahl, Robert Kramer, Ronald Richard, Sue Bailey and Zsolt Harsanyi.
View institutional ownership trends
.

How do I buy shares of Emergent BioSolutions?

Shares of EBS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Emergent BioSolutions' stock price today?

One share of EBS stock can currently be purchased for approximately $30.50.

How much money does Emergent BioSolutions make?

Emergent BioSolutions (NYSE:EBS) has a market capitalization of $1.52 billion and generates $1.79 billion in revenue each year. The biopharmaceutical company earns $230.90 million in net income (profit) each year or $1.69 on an earnings per share basis.

How many employees does Emergent BioSolutions have?

The company employs 2,416 workers across the globe.

How can I contact Emergent BioSolutions?

Emergent BioSolutions' mailing address is 400 PROFESSIONAL DR SUITE 400, GAITHERSBURG MD, 20879. The official website for the company is www.emergentbiosolutions.com. The biopharmaceutical company can be reached via phone at (240) 631-3200, via email at burrowsr@ebsi.com, or via fax at 301-795-1899.

This page (NYSE:EBS) was last updated on 8/13/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.